Overview
- TickerBHVN on NYSE1
- IndustryPharmaceutical Preparations1
- HeadquartersD81
- Websitewww.biohavenpharma.com
- Incorporated inVirgin Islands, British4
- Business address215 Church Street, New Haven, Ct 065104
- Filer categoryLarge accelerated filer4
See how the biggest companies compare on our leaderboards
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement in the latest annual report, as filed.8
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Research and development | $635.1M | $795.9M | $373.3M |
| General and administrative | $110.3M | $89.2M | $62.8M |
| Total operating expenses | $745.4M | $885.1M | $436.1M |
| Loss from operations | -$745.4M | -$885.1M | -$436.1M |
| Other income, net | $8.0M | $39.4M | $26.5M |
| Total other income, net | $8.0M | $39.4M | $26.5M |
| Loss before provision (benefit) for income taxes | -$737.4M | -$845.7M | -$409.6M |
| Provision (benefit) for income taxes | $1.4M | $735.0K | -$1.4M |
| Net loss | -$738.8M | -$846.4M | -$408.2M |
| Net loss per share basic (in dollars per share) | -$6.86 | -$9.28 | -$5.73 |
| Net loss per share diluted (in dollars per share) | -$6.86 | -$9.28 | -$5.73 |
| Weighted average common shares outstandingbasic (in shares) | 107.6M shares | 91.2M shares | 71.2M shares |
| Weighted average common shares outstandingdiluted (in shares) | 107.6M shares | 91.2M shares | 71.2M shares |
Every line of the balance sheet in the latest annual report, as filed.8
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $230.0M | $99.1M | $248.4M |
| Marketable securities | $89.2M | $386.9M | |
| Prepaid expenses | $47.0M | $49.4M | |
| Other current assets | $2.2M | $3.1M | |
| Total current assets | $368.3M | $538.5M | |
| Property and equipment, net | $16.0M | $17.3M | |
| Intangible assets | $18.4M | $18.4M | |
| Goodwill | $1.4M | $1.4M | |
| Other non-current assets | $47.4M | $39.5M | |
| Total assets | $451.4M | $615.1M | |
| Accounts payable | $11.6M | $18.0M | |
| Accrued expenses and other current liabilities | $104.3M | $51.5M | |
| Forward contract and derivative liability | $0 | $84.7M | |
| Total current liabilities | $115.9M | $154.2M | |
| Non-current operating lease liability | $40.0M | $32.8M | |
| Notes payable | $238.9M | $0 | |
| Other non-current liabilities | $4.6M | $4.7M | |
| Total liabilities | $399.4M | $191.7M | |
| Preferred shares, no par value; 10,000,000 shares authorized, no shares issued and outstanding as of December 31, 2025 and 2024 | $0 | $0 | |
| Common shares, no par value; 200,000,000 shares authorized as of December 31, 2025 and 2024; 132,775,113 and 101,221,989 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $1.9B | $1.7B | |
| Additional paid-in capital | $194.0M | $112.4M | |
| Accumulated deficit | -$2.1B | -$1.3B | |
| Accumulated other comprehensive income | $8.3M | $79.0K | |
| Total shareholders' equity | $52.1M | $423.4M | $428.0M |
| Total liabilities and shareholders' equity | $451.4M | $615.1M | |
| Preferred stock, par value (in dollars per share) | $0 | $0 | |
| Preferred stock, authorized (in shares) | 10.0M shares | 10.0M shares | |
| Preferred stock, issued (in shares) | 0 shares | 0 shares | |
| Preferred stock, outstanding (in shares) | 0 shares | 0 shares | |
| Common stock, par value (in dollars per share) | $0 | $0 | |
| Common stock, authorized (shares) | 200.0M shares | 200.0M shares | |
| Common stock, issued (shares) | 132.8M shares | 101.2M shares | |
| Common stock, outstanding (shares) | 132.8M shares | 101.2M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.8
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$738.8M | -$846.4M | -$408.2M |
| Non-cash share-based compensation | $112.4M | $72.0M | $28.8M |
| Acquisition of IPR&D asset | $0 | $10.8M | $0 |
| Depreciation and amortization | $9.9M | $7.9M | $6.9M |
| Issuance of common shares as payment for license agreement | $4.8M | $71.6M | $21.8M |
| Change in fair value of notes payable | -$8.7M | $0 | $0 |
| Obligation to issue common shares as payment for license agreements and other arrangements | $0 | $8.6M | $0 |
| Fair value of forward contract and derivative liabilities under license agreement | $0 | $102.5M | $0 |
| Change in fair value of forward contract and derivative liabilities | $9.4M | -$17.8M | $0 |
| Issuance of warrant under license agreement | $0 | $3.3M | $0 |
| Other non-cash items | $174.0K | -$11.7M | -$5.7M |
| Prepaid expenses, income tax receivable, and other current and non-current assets | $3.5M | $8.0M | $27.2M |
| Accounts payable | -$6.4M | $710.0K | $4.9M |
| Accrued expenses and other current and non-current liabilities | $4.2M | $8.1M | -$7.4M |
| Net cash used in operating activities | -$609.4M | -$582.5M | -$331.7M |
| Proceeds from maturities of marketable securities | $570.0M | $504.4M | $322.1M |
| Proceeds from sales of marketable securities | $0 | $0 | $4.9M |
| Purchases of marketable securities | -$266.9M | -$745.7M | -$194.1M |
| Purchases of property and equipment | -$715.0K | -$4.0M | -$3.0M |
| Cash acquired from acquisition of IPR&D asset | $0 | $391.0K | $0 |
| Other investing activities | -$1.8M | $0 | $0 |
| Net cash provided by (used in) investing activities | $300.6M | -$245.0M | $129.8M |
| Change in restricted cash due to Former Parent | $0 | $0 | -$35.2M |
| Proceeds from issuance of notes payable | $250.0M | $0 | $0 |
| Proceeds from issuance of common shares | $189.2M | $666.2M | $243.2M |
| Payments of issuance costs | -$1.7M | -$2.1M | -$800.0K |
| Proceeds from issuance of common shares under 2022 Equity Incentive Plan and 2022 Employee Share Purchase Plan | $1.8M | $11.5M | $4.7M |
| Other financing activities | -$194.0K | $2.3M | $0 |
| Net cash provided by financing activities | $439.1M | $677.8M | $211.9M |
| Effect of exchange rates on cash, cash equivalents and restricted cash | -$3.0K | $75.0K | -$497.0K |
| Net increase (decrease) in cash, cash equivalents and restricted cash | $130.2M | -$149.6M | $9.5M |
| Cash paid for interest | $216.0K | $125.0K | $0 |
Former names
- Biohaven Research Ltd.Jul 1, 2022 to Sep 14, 20224
Timeline
- May 2017Went public Listed on NYSE1
Recent filings
- Sep 17, 20264
- Sep 10, 20268-K
- Aug 26, 20268-K
- Aug 14, 2026SCHEDULE 13G
- Aug 14, 20263
- Aug 10, 202610-Q
- Aug 10, 20268-K
- Aug 7, 20268-K
- Jul 17, 20263
- Jul 9, 20268-K
- Jul 8, 2026SCHEDULE 13G/A
- May 27, 20268-K
- May 15, 2026SCHEDULE 13G/A
- May 5, 20268-K
- May 4, 20268-K
Every filing from the last three years, summarized. The full record is on SEC EDGAR.2
Links
- WikidataQ92546757
- SEC EDGARCIK 1935979
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3Company websiteBiohaven Pharmaceuticals logo
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11